-
1.发明申请Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent 有权组蛋白脱乙酰酶（Hdac）抑制剂（Pxd101）用于单独治疗癌症或与化疗药物组合公开(公告)号：US20080274120A1
公开(公告)日：2008-11-06
申请号：US12093069
申请日：2006-11-10
IPC分类号： A61K31/395 , A61K31/195 , A61P35/02 , C12N5/00 , A61P35/00
CPC分类号： A61K31/475 , A61K31/10 , A61K31/185 , A61K31/196 , A61K31/573 , A61K31/65 , A61K31/69 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要： The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin®, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
摘要翻译： 本发明一般涉及治疗癌症的方法。 在一个方面，本发明涉及一种治疗血液癌症（例如多发性骨髓瘤，白血病，淋巴瘤）的方法，包括向有需要的患者施用治疗有效量的组蛋白脱乙酰酶抑制剂，例如组蛋白脱乙酰酶 （HDAC）抑制剂，例如PXD-101。 在另一方面，本发明涉及一种治疗癌症的方法（例如，实体肿瘤癌症，例如直肠癌，结肠癌，卵巢癌;血液癌症，例如多发性骨髓瘤，白血病，淋巴瘤），其包括向患者施用 需要第一量的组蛋白脱乙酰酶（HDAC）抑制剂，例如本文所述的组蛋白脱乙酰酶抑制剂，例如PXD-101，和第二量的其它化学治疗剂，例如其它化学治疗剂 选自：针对VEGF的抗体，Avastin，针对CD20的抗体，利妥昔单抗，硼替佐米，沙利度胺，地塞米松，长春新碱，多柔比星和美法仑，其中第一和第二量一起包含治疗有效量。
-
公开(公告)号：US07056885B1
公开(公告)日：2006-06-06
申请号：US09609543
申请日：2000-07-03
申请人： Michael Jeffers , Richard A. Shimkets , Sudhirdas K. Prayaga , Ferenc L. Boldog , Meijia Yang , Catherine Burgess , Elma Fernandes , John L. Herrmann , William J. LaRochelle , Henri Lichenstein
发明人： Michael Jeffers , Richard A. Shimkets , Sudhirdas K. Prayaga , Ferenc L. Boldog , Meijia Yang , Catherine Burgess , Elma Fernandes , John L. Herrmann , William J. LaRochelle , Henri Lichenstein
CPC分类号： C07K14/50 , A61K38/00 , A61K48/00 , A61K2039/505
摘要： The present invention provides FGF-CX polypeptides and polynucleotides, and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods of use for the FGF-CX polypeptide, polynucleotide and antibody.
摘要翻译： 本发明提供FGF-CX多肽和多核苷酸，以及免疫特异性结合FGF-CX或FGF-CX多肽，多核苷酸或抗体的任何衍生物，变体，突变体或片段的抗体。 本发明另外提供了用于FGF-CX多肽，多核苷酸和抗体的方法。
-
公开(公告)号：US20050208514A1
公开(公告)日：2005-09-22
申请号：US10980659
申请日：2004-11-03
申请人： John Alsobrook , Ferenc Boldog , Michael Jeffers , William LaRochelle , Denise Lepley , Henri Lichenstein , Richard Shimkets , Meijia Yang , Marie Ruiz-Martinez , Galina Chernaya , Muralidhara Padigaru , Sudhirdas Prayaga , Mei Zhong
发明人： John Alsobrook , Ferenc Boldog , Michael Jeffers , William LaRochelle , Denise Lepley , Henri Lichenstein , Richard Shimkets , Meijia Yang , Marie Ruiz-Martinez , Galina Chernaya , Muralidhara Padigaru , Sudhirdas Prayaga , Mei Zhong
摘要： The present invention generally relates to nucleic acids, proteins, and antibodies. The invention relates more particularly to nucleic acid molecules, proteins, and antibodies of Fibroblast Growth Factor-20 (FGF-20), or its fragments, derivatives, variants, homologs, analogs, or a combination thereof.
摘要翻译： 本发明一般涉及核酸，蛋白质和抗体。 本发明更具体涉及成纤维细胞生长因子-20（FGF-20）或其片段，衍生物，变体，同系物，类似物或其组合的核酸分子，蛋白质和抗体。
-
公开(公告)号：US20060094647A1
公开(公告)日：2006-05-04
申请号：US09992840
申请日：2001-11-06
申请人： Michael Jeffers , Richard Shimkets , Sudhirdas Prayaga , Ferenc Boldog , Meijia Yang , Catherine Burgess , Elma Fernandes , Beth Rittman , Juliette Shimkets , William LaRochelle , Henri Lichenstein
发明人： Michael Jeffers , Richard Shimkets , Sudhirdas Prayaga , Ferenc Boldog , Meijia Yang , Catherine Burgess , Elma Fernandes , Beth Rittman , Juliette Shimkets , William LaRochelle , Henri Lichenstein
IPC分类号： A61K38/17
CPC分类号： A61K38/1825 , C07K14/49 , C07K14/50 , C07K14/51 , C07K14/52
摘要： The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotide sequences and the FGF-CX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
摘要翻译： 本发明是基于使用生长因子相关多肽治疗哺乳动物肠道炎症状况的方法。 在本发明中要求使用成纤维细胞生长因子CX（FGF-CX）多核苷酸序列和由这种核酸序列编码的FGF-CX多肽或其变体，片段和同系物的方法。 类似地，在本发明中还要求保护使用FCTRX多核苷酸序列和由此类核酸序列编码的FCTRX多肽，或其变体，片段和同源物单独或组合使用的方法。 FCTRX统称为六种变体FCTRX序列中的任何一种，分别为FCTR1，FCTR2，FCTR3，FCTR4，FCTR5和FCTR6。
-
公开(公告)号：US20050171020A1
公开(公告)日：2005-08-04
申请号：US11096308
申请日：2005-04-01
摘要： Disclosed are novel nucleic acids encoding proteins and polypeptides related to bone morphogenetic protein-1 (BMF1) and to vascular endothelial growth factor E (VEGF-E).
摘要翻译： 公开了编码与骨形态发生蛋白-1（BMF1）和血管内皮生长因子E（VEGF-E）相关的蛋白质和多肽的新型核酸。
-
公开(公告)号：US20050164929A1
公开(公告)日：2005-07-28
申请号：US10980764
申请日：2004-11-03
IPC分类号： A61K38/00 , A61K38/18 , A61K38/19 , C07K14/49 , C07K14/50 , C07K14/51 , C07K14/52 , A61K48/00 , A61K38/17
摘要： The present invention relates to compositions and methods for preventing and treating an inflammatory disorder of a mucosa, including but is not limited to, inflammatory bowel disease and irritable bowel syndrome. More particularly, the present invention relates to compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof, and their uses in preventing and treating an inflammatory disorder of a mucosa, such as inflammatory bowel disease or irritable bowel syndrome.
摘要翻译： 本发明涉及用于预防和治疗粘膜炎症性疾病的组合物和方法，包括但不限于炎性肠病和肠易激综合征。 更具体地，本发明涉及包含FGF-20，片段，衍生物，变体，同源物或类似物的组合物，以及它们在预防和治疗粘膜炎症性疾病如炎症性肠病中的用途 或肠易激综合征。
-
公开(公告)号：US5326858A
公开(公告)日：1994-07-05
申请号：US921371
申请日：1992-07-28
申请人： Henri Lichenstein , Keith Langley , Mark Zukowski
发明人： Henri Lichenstein , Keith Langley , Mark Zukowski
IPC分类号： G01N33/573 , A61K38/00 , A61K38/46 , A61P31/04 , C07K16/40 , C12N9/36 , C12N15/09 , C12N15/56 , C12Q1/68 , C12R1/465 , C07H21/04 , A61K37/54
CPC分类号： C12N9/2462 , C07K16/40 , A61K38/00
摘要： Disclosed are DNA sequences encoding N-acetylmuramidase M1, polypeptide products of recombinant expression of these DNA sequences, peptides whose sequences are based upon the amino acid sequences deduced from these DNA sequences, antibodies specific for such proteins and peptides, procedures for the detection and quantitation of such proteins and nucleic acids related thereto, as well as procedures relating to the development of bacteriolytic methods, therapeutic agents, and compositions utilizing N-acetylmuramidase M1.
摘要翻译： 公开了编码N-乙酰神经酰胺酶M1的DNA序列，这些DNA序列的重组表达的多肽产物，其序列基于从这些DNA序列推导出的氨基酸序列，对这些蛋白质和肽特异的抗体，检测和定量的方法 的这些蛋白质和与其相关的核酸，以及涉及使用N-乙酰神经酰胺酶M1的细菌溶解方法，治疗剂和组合物的发展的方法。
-
8.发明授权Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent 有权组蛋白脱乙酰酶（HDAC）抑制剂（PXD101）用于单独治疗癌症或与化学治疗剂组合公开(公告)号：US08828392B2
公开(公告)日：2014-09-09
申请号：US12093069
申请日：2006-11-10
IPC分类号： A61K39/395 , A01N37/28 , C12N5/02 , C12N5/0781 , C12N5/09 , A61K31/10 , A61K31/65 , A61K31/573 , A61K31/475 , A61K45/06 , A61K31/196
CPC分类号： A61K31/475 , A61K31/10 , A61K31/185 , A61K31/196 , A61K31/573 , A61K31/65 , A61K31/69 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要： The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumor cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN® (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
摘要翻译： 本发明一般涉及治疗癌症的方法。 在一个方面，本发明涉及一种治疗血液癌症（例如多发性骨髓瘤，白血病，淋巴瘤）的方法，包括向有需要的患者施用治疗有效量的组蛋白脱乙酰酶抑制剂，例如组蛋白脱乙酰酶 （HDAC）抑制剂，例如PXD-101。 在另一方面，本发明涉及一种治疗癌症的方法（例如，实体肿瘤癌症，例如直肠癌，结肠癌，卵巢癌;血液癌症，例如多发性骨髓瘤，白血病，淋巴瘤），其包括向患者施用 需要第一量的组蛋白脱乙酰酶（HDAC）抑制剂，例如本文所述的组蛋白脱乙酰酶抑制剂，例如PXD-101，和第二量的其它化学治疗剂，例如其它化学治疗剂 选自：抗VEGF抗体（贝伐单抗），抗CD20抗体，利妥昔单抗，硼替佐米，沙利度胺，地塞米松，长春新碱，多柔比星和美法仑，其中第一和第二量一起包含治疗有效量。
-
公开(公告)号：US20080287349A1
公开(公告)日：2008-11-20
申请号：US10980458
申请日：2004-11-03
申请人： Jeffrey Peterson , Paul Sciore , Erik Gunther , Marie Ruiz-Martinez , Galina Chernaya , William J. LaRochelle , Michael E. Jeffers , Henri Lichenstein , Peter Mezes
发明人： Jeffrey Peterson , Paul Sciore , Erik Gunther , Marie Ruiz-Martinez , Galina Chernaya , William J. LaRochelle , Michael E. Jeffers , Henri Lichenstein , Peter Mezes
IPC分类号： A61K38/17 , A61K31/711 , C07H21/04 , C12N15/63 , C12N5/06 , C12N1/00 , C12P21/00 , C07K14/00 , A61P19/00 , A61P19/02
CPC分类号： A61K38/1825 , A61K31/711 , C07K14/50
摘要： The present invention relates to compositions and methods for preventing and treating a disease (e.g., a joint disease, ischemic stroke, hemorrhagic stroke, trauma, spinal cord damage, heavy metal or toxin poisoning, or neurodegenerative diseases). More particularly, the present invention provides methods for preventing and/or treating a disease (e.g., a joint disease, ischemic stroke, hemorrhagic stroke, trauma, spinal cord damage, heavy metal or toxin poisoning, or neurodegenerative diseases) by using compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof.
摘要翻译： 本发明涉及用于预防和治疗疾病（例如关节疾病，缺血性中风，出血性中风，创伤，脊髓损伤，重金属或毒素中毒或神经变性疾病）的组合物和方法。 更具体地，本发明通过使用包含FGF的组合物提供了预防和/或治疗疾病（例如关节疾病，缺血性中风，出血性中风，创伤，脊髓损伤，重金属或毒素中毒或神经变性疾病）的方法 -20，片段，衍生物，变体，同系物或其类似物。
-
公开(公告)号：US20050256042A1
公开(公告)日：2005-11-17
申请号：US10980459
申请日：2004-11-03
申请人： Michael Jeffers , Zachary Yim , Pascal Valax , Pradyumna Namdev , Rajeev Chillakuru , William LaRochelle , Henri Lichenstein , Enrique Alvarez , William Hahne
发明人： Michael Jeffers , Zachary Yim , Pascal Valax , Pradyumna Namdev , Rajeev Chillakuru , William LaRochelle , Henri Lichenstein , Enrique Alvarez , William Hahne
摘要： The present invention relates to compositions and methods for preventing and treating alimentary mucositis. More particularly, the present invention provides methods for preventing and/or treating alimetary mucositis by using compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof.
摘要翻译： 本发明涉及预防和治疗消化性粘膜炎的组合物和方法。 更具体地，本发明提供了通过使用包含FGF-20，片段，衍生物，变体，同源物或类似物的组合物来预防和/或治疗哺乳动物粘膜炎的方法。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.028 秒)
